Navigation Links
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Date:4/2/2008

ent to production and sale of vaccines.

One goal is to complete the registration of IMVAMUNE(R). The vaccine will then be commercialized via sales to the United States and other countries.

In addition, the intention is to build up a biodefense portfolio of projects that can complement IMVAMUNE(R) and ensure the Company a sustained and growing business.

As part of building up this portfolio, Bavarian Nordic has initiated a preclinical program for an anthrax vaccine. The Company sees a number of synergies - both in the development and in market approach which support the development of such a vaccine. Also, it is expected that a combined anthrax and smallpox vaccine can be developed and thus Bavarian Nordic would be able to offer one vaccine against two of the top biological threats. The anthrax program is expected to enter Phase I in 2008.

Cancer

In the short term, the goal is to complete the Phase I/II studies of the vaccine candidate for breast cancer and to initiate Phase I/II studies of the vaccine candidate for prostate cancer.

As and when positive clinical data are obtained, partnering of the projects will be considered and the Company will also keep an eye on potential in-licensing opportunities.

The cancer business area has been given a higher priority and it is the Company's goal to expand the cancer portfolio. Later in 2008 the Company expects to announce initiatives to strengthen this area.

Infectious diseases

The Company has a number of projects in infectious diseases, all of which are at an early development stage: HIV, measles and RSV, dengue fever and Japanese encephalitis. The goal with the first two projects is to complete early-stage clinical trials. If supported by the data obtained, the option of placing these projects in external partnerships will be explored. Alternatively, the Company will seek other external funding. For the latter two projects, discussions with a potential externa
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
9. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
(Date:12/15/2014)... BEIJING , Dec. 15, 2014  Origin Agritech Limited ... "), a technology-focused supplier of crop seeds in ... results for its fiscal year 2014 ended September 30, 2014, ... The Company will host a teleconference on January 8, ... Beijing time to discuss the results. To participate ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Than rituximab ... in a Pre-Clinical Study, ... that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement dependent cytotoxicity ... study. The CD20,antibodies were incubated with tumor cells and analyzed ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... Chief Financial Officer and James Weaver as Chairman, ... ILI ) announced today that Thomas Gerson has been ... Weaver as,Chairman of the Board of Directors. In addition, ... and Development. "We are pleased to welcome Tom ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2IBM and Imago find a crucial difficulty in semiconductor device scaling 2Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Six researchers from the Technische Universitaet Muenchen are ... bring around ten million euros to support pioneering ... investigate the impact of extreme weather events on ... magnetic vortices for enhanced data processing. Prof. Rdiger ...
... among South Asians to be recalculated has been published by ... from the University,s Departments of Health Sciences and Cardiovascular Sciences ... Asians should be classed as obese to be redefined. ... a journal of the Public Library of Science. South ...
... 2004 as a three-person start-up may well be on ... Advanced by a team of young Dutch scientists pushing ... is attracting the attention of some key investors and ... to innovative SMES, with the Eurostars funding programme leading ...
Cached Biology News:10 million euros for pioneering research projects at TU Muenchen 210 million euros for pioneering research projects at TU Muenchen 310 million euros for pioneering research projects at TU Muenchen 410 million euros for pioneering research projects at TU Muenchen 510 million euros for pioneering research projects at TU Muenchen 610 million euros for pioneering research projects at TU Muenchen 7New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Biology Products: